Salix ( Salix )

Salix

Salix's picture

Salix Pharmaceuticals, Inc. is a specialist American pharmaceutical company. As of March 2015 it was the largest independent gastrointestinal specialty pharmaceutical company in the world. The company develops prescription drugs and medical devices that prevent and treat various gastrointestinal disorders.

Salix press release, blog etc

07/01/2014 - 07:15 Salix Announces Statistically Significant Primary Endpoint Result For Target 3 Evaluating The Efficacy And Safety Of Repeat Treatment With Rifaximin 550mg In Subjects With Irritable Bowel Syndrome With Diarrhea
06/12/2014 - 15:36 FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC
05/28/2014 - 06:36 Salix Pharmaceuticals To Present At Three Investment Conferences In June
05/06/2014 - 04:13 Salix Pharmaceuticals to Present at Two Investment Conferences in May
05/05/2014 - 06:09 Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2014
04/24/2014 - 06:05 Salix Pharmaceuticals Announces 1Q2014 Financial Results Conference Call and Webcast
04/22/2014 - 04:27 Salix Pharmaceuticals and Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand the Use of Relistor in Chronic Non-Cancer Pain by the European Medicines Agency
03/04/2014 - 10:08 Salix Pharmaceuticals To Present At ROTH Conference
02/27/2014 - 11:06 Salix Pharmaceuticals and RedHill Biopharma Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
02/25/2014 - 13:03 Salix Wins Napo Pharmaceuticals Litigation
02/13/2014 - 08:07 Salix Pharmaceuticals Announces 4Q and FY2013 Financial Results Conference Call and Webcast
02/04/2014 - 06:08 Salix Pharmaceuticals Announces Issuance of U.S. Patent for Rifaximin
01/30/2014 - 18:02 Salix Announces Acceptance of NDA Filing For Budesonide Foam in Patients with Distal Ulcerative Colitis
01/14/2014 - 09:53 Fulyzaq® (crofelemer) 125 mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea in Adult Patients Living with HIV on ART Therapy
01/13/2014 - 09:48 Salix Pharmaceuticals Provides Post-Merger Update
01/08/2014 - 07:48 Advancing Treatment in Gastroenterology™
01/02/2014 - 14:57 Salix Pharmaceuticals Completes Acquisition of Santarus
12/10/2013 - 07:49 Salix Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Santarus